Kevin McCulloch - Xeris Pharmaceuticals Chief Officer
| XERS Stock | USD 4.56 0.01 0.22% |
Insider
Kevin McCulloch is Chief Officer of Xeris Pharmaceuticals
| Phone | 844 445 5704 |
| Web | https://www.xerispharma.com |
Xeris Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.0533) % which means that it has lost $0.0533 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (6.1716) %, meaning that it created substantial loss on money invested by shareholders. Xeris Pharmaceuticals' management efficiency ratios could be used to measure how well Xeris Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Henric Bjarke | Inozyme Pharma | 57 | |
| Stefan Riley | Inozyme Pharma | N/A | |
| John Lewicki | Mereo BioPharma Group | 73 | |
| Mark Vignola | Terns Pharmaceuticals | 47 | |
| Jeff York | Seres Therapeutics | N/A | |
| James Balkovec | Cidara Therapeutics | N/A | |
| Keith MD | X4 Pharmaceuticals | 54 | |
| Mary DiBiase | X4 Pharmaceuticals | 64 | |
| Alexandra HughesWilson | Mereo BioPharma Group | 54 | |
| PharmD Chiodin | Day One Biopharmaceuticals | N/A | |
| RPh PharmD | Elevation Oncology | 40 | |
| David MBA | Seres Therapeutics | 63 | |
| Kristin Ainsworth | Seres Therapeutics | N/A | |
| Kerry MD | Terns Pharmaceuticals | N/A | |
| Arthur Taveras | X4 Pharmaceuticals | 61 | |
| Prof MD | Hookipa Pharma | 81 | |
| Christine CPA | Mereo BioPharma Group | 44 | |
| MA MS | Inozyme Pharma | N/A | |
| Janetta Trochimiuk | PDS Biotechnology Corp | 62 | |
| Valerie MD | Elevation Oncology | 47 | |
| MBA MBA | Inozyme Pharma | 65 | |
Management Performance
| Return On Equity | -6.17 | ||||
| Return On Asset | -0.0533 |
Xeris Pharmaceuticals Leadership Team
Elected by the shareholders, the Xeris Pharmaceuticals' board of directors comprises two types of representatives: Xeris Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Xeris. The board's role is to monitor Xeris Pharmaceuticals' management team and ensure that shareholders' interests are well served. Xeris Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Xeris Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Anh Nguyen, Chief Officer | ||
| PharmD D, Senior Affairs | ||
| Beth JD, Chief Secretary | ||
| Steven Pieper, Chief Officer | ||
| Dr MBA, CoFounder Officer | ||
| Paul JD, Senior Advisor | ||
| Kendal Korte, Senior Resources | ||
| Brian Conner, SVP Officer | ||
| Allison Wey, Senior Communications | ||
| MD MBA, Chief Officer | ||
| Paul Edick, President CEO, Director | ||
| John Shannon, President COO | ||
| Kevin McCulloch, Chief Officer |
Xeris Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Xeris Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -6.17 | ||||
| Return On Asset | -0.0533 | ||||
| Profit Margin | (0.27) % | ||||
| Operating Margin | 0.13 % | ||||
| Current Valuation | 874.08 M | ||||
| Shares Outstanding | 153.94 M | ||||
| Shares Owned By Insiders | 3.99 % | ||||
| Shares Owned By Institutions | 42.86 % | ||||
| Number Of Shares Shorted | 10.27 M | ||||
| Price To Book | 3.34 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Xeris Stock Analysis
When running Xeris Pharmaceuticals' price analysis, check to measure Xeris Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xeris Pharmaceuticals is operating at the current time. Most of Xeris Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Xeris Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xeris Pharmaceuticals' price. Additionally, you may evaluate how the addition of Xeris Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.